HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bone marrow transplantation from unrelated donors for patients with adult T-cell leukaemia/lymphoma.

Abstract
Adult T-cell leukaemia/lymphoma (ATLL) is a highly aggressive haematological malignancy. More than 40 cases of ATLL treated by allogeneic bone marrow transplantation (BMT) from sibling donors have been reported, while there have been only a few cases of unrelated BMT for treatment of this disease. We began performing allogeneic BMT from unrelated donors in 1999 to improve the outcome of ATLL patients with no suitable sibling donors. Eight ATLL patients underwent unrelated BMT; five received the conventional conditioning regimen consisting of cyclophosphamide and total body irradiation, while three received a reduced-intensity preparative regimen. Two patients died due to encephalopathy of unknown aetiology on days 10 and 35, and one patient died due to progression of ATLL 25 months after BMT. Five patients are currently alive and disease-free at a median of 20 months after BMT. Proviral human T-lymphotropic virus type-I (HTLV-I) DNA load in peripheral blood mononuclear cells (PBMCs) was assessed in four cases before and after BMT. HTLV-I proviral DNA load was reduced significantly after transplantation. Unrelated BMT is feasible for treatment of ATLL. Further studies in a larger number of cases are required to determine the optimal conditioning regimen and stem cell source.
AuthorsK Nakase, M Hara, T Kozuka, K Tanimoto, Y Nawa
JournalBone marrow transplantation (Bone Marrow Transplant) Vol. 37 Issue 1 Pg. 41-4 (Jan 2006) ISSN: 0268-3369 [Print] England
PMID16247419 (Publication Type: Journal Article)
Chemical References
  • Myeloablative Agonists
  • Cyclophosphamide
Topics
  • Bone Marrow Transplantation
  • Cyclophosphamide (administration & dosage)
  • Disease-Free Survival
  • Female
  • Histocompatibility Testing
  • Humans
  • Leukemia-Lymphoma, Adult T-Cell (blood, mortality, therapy)
  • Living Donors
  • Male
  • Middle Aged
  • Myeloablative Agonists (administration & dosage)
  • Retrospective Studies
  • Transplantation Conditioning
  • Transplantation, Homologous
  • Whole-Body Irradiation (methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: